Curium to Acquire Lantheus in Up to $8 Billion Radiopharma Deal
Curium will buy Lantheus for $102.50/share cash plus up to $12 CVRs, valuing the radiopharma deal at up to $8B. Closing expected in H1 2027.
/ 352 items
#XY Event-Driven Stocks↓
Supernus and Indivior Agree to Merge, Creating $2.2 Billion CNS Biopharma Leader
Supernus and Indivior merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility.
KKR to Buy Integer Holdings for $5.7 Billion in All-Cash Deal
Shareholders get cash; company goes private by year-end.
Novo Nordisk’s Anti-Inflammatory Drug Fails Key Heart Trial
Novo Nordisk’s ziltivekimab failed to reduce major cardiovascular events in the late-stage ZEUS trial of high-risk patients.
Seer Board Reviews Competing Takeover Bids from Activists and Its Own CEO
Seer confirms two revised unsolicited offers: $2.55 + CVR from Radoff-JEC Group and $2.45 + two CVRs from CEO Farokhzad. Special committee reviewing.
Abivax Gets Positive FDA Feedback, Stays on Track to File for New Ulcerative Colitis Drug by End of 2026
Abivax completes positive pre-NDA meeting with FDA for obefazimod in ulcerative colitis, stays on track for 2026 filing, with $3-5B peak sales potential.